{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:28:51Z","timestamp":1792056531250,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.resinv.2024.11.003","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T19:25:02Z","timestamp":1731612302000},"page":"1242-1246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advancements in the treatment of interstitial lung disease in systemic sclerosis with the approval of mycophenolate mofetil"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5887-8375","authenticated-orcid":false,"given":"Toshinori","family":"Takada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7428-1245","authenticated-orcid":false,"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2024.11.003_bib1","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2024.11.003_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/acr.21583","article-title":"Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis","volume":"64","author":"Steele","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.resinv.2024.11.003_bib3","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/art.39405","article-title":"Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease","volume":"67","author":"Suliman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resinv.2024.11.003_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib5","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","article-title":"Systemic sclerosis-associated interstitial lung disease","volume":"8","author":"Perelas","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American thoracic society clinical practice guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.resinv.2017.11.004","article-title":"Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis","volume":"56","author":"Ueda","year":"2018","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2024.11.003_bib9","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00000478-199402000-00003","article-title":"Nonspecific interstitial pneumonia\/fibrosis. Histologic features and clinical significance","volume":"18","author":"Katzenstein","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.resinv.2024.11.003_bib11","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1164\/ajrccm.158.4.9802119","article-title":"Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients","volume":"158","author":"Cottin","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/thoraxjnl-2013-203843","article-title":"Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants","volume":"69","author":"Walsh","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2024.11.003_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.11.003_bib14","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2024.11.003_bib15","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2024.11.003_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2024.11.003_bib17","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib18","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resinv.2024.11.003_bib20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/ard.2004.033076","article-title":"Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations","volume":"64","author":"Kowal-Bielecka","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2024.11.003_bib21","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2024.11.003_bib23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/keaa550","article-title":"Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis","volume":"60","author":"Goswami","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2024.11.003_bib24","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2024.11.003_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00235-2020","article-title":"Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review","volume":"7","author":"Hoffmann-Vold","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2024.11.003_bib26","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.resinv.2024.11.003_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000384","article-title":"Rituximab in early systemic sclerosis","volume":"3","author":"Boonstra","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.resinv.2024.11.003_bib29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2024.11.003_bib30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib31","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib32","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib33","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.41576","article-title":"Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of a randomized, double-blind, placebo-controlled trial","volume":"73","author":"Maher","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resinv.2024.11.003_bib35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.11.003_bib36","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resinv.2024.11.003_bib37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.resinv.2024.11.003_bib38","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T08:53:02Z","timestamp":1732092782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534524001722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2212534524001722"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2024.11.003","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements in the treatment of interstitial lung disease in systemic sclerosis with the approval of mycophenolate mofetil","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2024.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}